BTIG Reiterates Buy on Apogee Therapeutics, Maintains $137 Price Target

BTIG analyst Julian Harrison has reiterated a Buy rating on Apogee Therapeutics (NASDAQ: APGE) and maintained a price target of $137 for the stock. This endorsement suggests confidence in the company's future performance.